Efficacy_NN of_IN Quinupristin-Dalfopristin_NP in_IN Preventing_NP Vascular_NP Graft_NP Infection_NP Due_NP to_TO Staphylococcus_NP epidermidis_NNS with_IN Intermediate_NP Resistance_NP to_TO Glycopeptides_NP A_DT rat_NN model_NN was_VBD used_VBN to_TO investigate_VB the_DT efficacy_NN of_IN quinupristin-dalfopristin_NP (_( Q-D_NP )_) in_IN the_DT prevention_NN of_IN vascular_JJ prosthetic_JJ graft_NN infection_NN due_JJ to_TO methicillin-resistant_JJ Staphylococcus_NP epidermidis_NNS with_IN intermediate_JJ resistance_NN to_TO glycopeptides_NNS ._SENT The_DT in_IN vitro_NN activity_NN of_IN the_DT compound_NN was_VBD compared_VBN to_TO that_DT of_IN vancomycin_NP by_IN MIC_JJ determination_NN and_CC time-kill_NN study_NN ._SENT Moreover_RB ,_, the_DT efficacy_NN of_IN collagen-sealed_JJ Q-D-soaked_NP Dacron_NP was_VBD evaluated_VBN in_IN a_DT rat_NN model_NN of_IN graft_NN infection_NN ._SENT Graft_NN infections_NNS were_VBD established_VBN in_IN the_DT subcutaneous_JJ tissue_NN of_IN the_DT backs_NNS of_IN 120_CD adult_NN male_JJ Wistar_NP rats_NNS ._SENT The_DT in_IN vivo_JJ study_NN included_VBD a_DT control_NN group_NN ,_, one_CD contaminated_JJ group_NN that_WDT did_VBD not_RB receive_VB any_DT antibiotic_JJ prophylaxis_NN ,_, two_CD contaminated_JJ groups_NNS that_WDT received_VBD grafts_NNS soaked_VBN with_IN 10_CD and_CC 100_CD mug_NN of_IN Q-D_NNS per_IN ml_NN ,_, respectively_RB ,_, and_CC two_CD contaminated_JJ groups_NNS that_WDT received_VBD grafts_NNS soaked_VBN with_IN 10_CD and_CC 100_CD mug_NN of_IN vancomycin_NP per_IN ml_NN ,_, respectively_RB ._SENT Rats_NNS that_WDT received_VBD Dacron_NP grafts_NNS soaked_VBD with_IN 100_CD mug_NN of_IN Q-D_NNS per_IN ml_NN showed_VBD no_DT evidence_NN of_IN infection_NN (_( <10_NP CFU/ml_NP )_) ._SENT In_IN contrast_NN ,_, for_IN rats_NNS that_WDT received_VBD Dacron_NP grafts_NNS soaked_VBD with_IN 10_CD mug_NN of_IN Q-D_NNS per_IN ml_NN and_CC Dacron_NN grafts_NNS soaked_VBN with_IN 10_CD or_CC 100_CD mug_NN of_IN vancomycin_NP per_IN ml_NN ,_, the_DT quantitative_JJ graft_NN cultures_NNS demonstrated_VBD 2.2_CD x_SYM 102_CD +-_NN 1.3_CD x_NN 102_CD ,_, 2.2_CD x_SYM 106_CD +-_NN 1.9_CD x_NN 105_CD ,_, and_CC 5.6_CD x_SYM 102_CD +-_NN 0.3_CD x_SYM 102_CD CFU/ml_NN ,_, respectively_RB ._SENT Taken_VBN together_RB the_DT results_NNS of_IN the_DT study_NN demonstrate_VBP that_IN the_DT use_NN of_IN Dacron_NP grafts_NNS soaked_VBN with_IN Q-D_NP can_MD result_VB in_IN significant_JJ bacterial_JJ growth_NN inhibition_NN and_CC show_VBP that_IN this_DT compound_NN is_VBZ potentially_RB valuable_JJ for_IN prevention_NN of_IN vascular_JJ prosthetic_JJ graft_NN infection_NN ._SENT The_DT increasing_VBG use_NN of_IN foreign_JJ material_NN in_IN many_JJ fields_NNS of_IN modern_JJ surgery_NN is_VBZ associated_VBN with_IN a_DT definitive_JJ risk_NN of_IN bacterial_JJ infection_NN ._SENT Coagulase-negative_JJ staphylococci_NNS ,_, chiefly_RB the_DT skin_NN commensal_JJ Staphylococcus_NP epidermidis_NNS ,_, are_VBP among_IN the_DT most_RBS common_JJ pathogens_NNS that_WDT cause_VBP biomaterial_JJ infections_NNS and_CC the_DT most_RBS frequent_JJ cause_NN of_IN late-appearing_VBG vascular_JJ graft_NN infections_NNS in_IN humans_NNS ._SENT Vascular_JJ prosthetic_JJ graft_NN infection_NN is_VBZ one_CD of_IN the_DT most_RBS feared_JJ complications_NNS that_IN the_DT vascular_JJ surgeon_NN treats_NNS ;_: although_IN most_JJS cases_NNS are_VBP resolved_VBN by_IN removal_NN of_IN the_DT device_NN and_CC antibiotic_JJ therapy_NN ,_, serious_JJ complications_NNS may_MD result_VB ,_, including_VBG organ_NN failure_NN ,_, amputation_NN ,_, metastatic_JJ infection_NN ,_, and_CC death_NN ._SENT Effective_JJ strategies_NNS for_IN the_DT prevention_NN of_IN prosthetic_JJ infection_NN vary_VBP from_IN device_NN to_TO device_NN ._SENT The_DT centerpieces_NNS of_IN prophylaxis_NN are_VBP asepsis_NN and_CC perioperative_JJ administration_NN of_IN systemic_JJ antibiotics_NNS ._SENT As_IN adjunctive_JJ prophylaxis_NN ,_, in_IN the_DT case_NN of_IN vascular_JJ grafts_NNS ,_, the_DT use_NN of_IN antimicrobials_NNS that_WDT bind_VBP to_TO prosthetic_JJ grafts_NNS at_IN high_JJ concentrations_NNS has_VBZ been_VBN proposed_VBN ._SENT Since_IN the_DT emergence_NN of_IN methicillin-resistant_JJ staphylococci_NNS ,_, glycopeptides_NNS have_VBP often_RB been_VBN the_DT only_JJ effective_JJ drugs_NNS ._SENT For_IN this_DT reason_NN ,_, the_DT emergence_NN of_IN staphylococcal_JJ strains_NNS exhibiting_VBG reduced_VBN sensitivities_NNS to_TO vancomycin_NP is_VBZ of_IN particular_JJ concern_NN ._SENT The_DT emergence_NN of_IN vancomycin_NP resistance_NN in_IN coagulase-negative_JJ staphylococci_NNS was_VBD described_VBN in_IN the_DT 1980s_NNS ._SENT For_IN this_DT reason_NN ,_, new_JJ strategies_NNS are_VBP needed_VBN to_TO treat_VB infections_NNS caused_VBN by_IN these_DT multidrug-resistant_JJ organisms_NNS and_CC to_TO reduce_VB the_DT increasing_VBG selection_NN pressure_NN of_IN antibiotics_NNS on_IN gram-positive_JJ pathogens_NNS ._SENT Various_JJ new_JJ agents_NNS have_VBP been_VBN demonstrated_VBN to_TO have_VB significant_JJ in_IN vitro_NN activities_NNS against_IN staphylococci_NNS ._SENT One_CD of_IN these_DT compounds_NNS is_VBZ the_DT new_JJ semisynthetic_JJ injectable_JJ streptogramin_NN quinupristin-dalfopristin_NP (_( Q-D_NP )_) ,_, composed_VBN of_IN two_CD components_NNS which_WDT may_MD act_VB synergistically_RB :_: quinupristin_NP ,_, a_DT peptide_NN macrolactone_NN classified_VBN as_IN a_DT type_NN B_NN streptogramin_NN ,_, and_CC dalfopristin_NP ,_, a_DT polyunsaturated_JJ macrolactone_NN classified_VBN as_IN a_DT type_NN A_DT streptogramin_NN ,_, in_IN a_DT 30:70_CD ratio_NN ._SENT It_PP has_VBZ a_DT focused_VBN spectrum_NN of_IN in_IN vitro_NN activity_NN against_IN gram-positive_JJ cocci_NNS ,_, including_VBG multidrug-resistant_JJ isolates_NNS of_IN staphylococci_NNS ,_, streptococci_NNS ,_, and_CC Enterococcus_NP faecium_NN ._SENT In_IN this_DT study_NN we_PP used_VBD one_CD strain_NN of_IN S._NP epidermidis_NNS with_IN intermediate_JJ resistance_NN to_TO vancomycin_NP to_TO investigate_VB the_DT in_IN vitro_NN activity_NN of_IN Q-D_NP and_CC its_PP$ in_IN vivo_JJ efficacy_NN when_WRB it_PP was_VBD bound_VBN to_TO a_DT Dacron_NP graft_NN for_IN the_DT prevention_NN of_IN prosthesis_NN infection_NN in_IN a_DT rat_NN model_NN ._SENT In_IN vitro_NN studies_NNS ._SENT (_( i_NP )_) Organisms_NNS ._SENT |_SYM The_DT strain_NN of_IN methicillin-resistant_JJ S._NP epidermidis_NNS with_IN intermediate_JJ resistance_NN to_TO vancomycin_NP used_VBN in_IN this_DT study_NN was_VBD isolated_VBN from_IN a_DT clinical_JJ specimen_NN submitted_VBN for_IN routine_JJ bacteriological_JJ investigation_NN to_TO the_DT Institute_NP of_IN Infectious_NP Diseases_NPS and_CC Public_NP Health_NP ,_, University_NP of_IN Ancona_NP ,_, Ancona_NP ,_, Italy_NP ._SENT This_DT isolate_NN is_VBZ described_VBN by_IN use_NN of_IN the_DT acronym_NN VISE_NP (_( vancomycin-intermediate_NP S._NP epidermidis_NNS )_) ._SENT Commercially_RB available_JJ S._NP epidermidis_NNS ATCC_NP 12228_CD was_VBD used_VBN as_IN a_DT quality_NN control_NN strain_NN in_IN the_DT in_IN vitro_NN investigations_NNS ._SENT (_( ii_NP )_) Drugs_NP ._SENT |_SYM Q-D_NN was_VBD obtained_VBN from_IN Aventis_NP Pharma_NP ,_, Centre_NP de_NP Recherches_NP ,_, Vitry-Alfortville_NP ,_, France_NP ._SENT Vancomycin_NP was_VBD obtained_VBN from_IN Sigma-Aldrich_NP ,_, Milan_NP ,_, Italy_NP ._SENT Laboratory_NN powders_NNS were_VBD diluted_VBN in_IN accordance_NN with_IN the_DT recommendations_NNS of_IN the_DT manufacturers_NNS ._SENT Solutions_NNS of_IN drugs_NNS were_VBD made_VBN fresh_JJ on_IN the_DT day_NN of_IN assay_NN or_CC were_VBD stored_VBN at_IN -80C_NN in_IN the_DT dark_NN for_IN up_IN to_TO 20_CD days_NNS ._SENT (_( iii_NP )_) Antimicrobial_JJ susceptibility_NN testing_NN ._SENT |_SYM The_DT antimicrobial_JJ susceptibilities_NNS of_IN the_DT strains_NNS to_TO Q-D_NP and_CC vancomycin_NP were_VBD determined_VBN by_IN the_DT broth_NN microdilution_NN method_NN described_VBN by_IN the_DT National_NP Committee_NP for_IN Clinical_NP Laboratory_NP Standards_NP (_( NCCLS_NP )_) ._SENT In_IN addition_NN ,_, the_DT strains_NNS were_VBD tested_VBN for_IN their_PP$ susceptibilities_NNS to_TO vancomycin_NP by_IN the_DT NCCLS_NP reference_NN disk_NN diffusion_NN method_NN with_IN 30-mug_JJ vancomycin_NP discs_NNS ._SENT Experiments_NNS were_VBD performed_VBN in_IN triplicate_NN ._SENT (_( iv_NP )_) Time-kill_NP studies_NNS ._SENT |_SYM To_TO perform_VB time-kill_NN studies_NNS ,_, the_DT VISE_NP strain_NN was_VBD grown_VBN at_IN 37C_JJ in_IN Mueller-Hinton_NP (_( MH_NP )_) broth_NN ._SENT When_WRB the_DT bacteria_NNS were_VBD in_IN the_DT log_NN phase_NN of_IN growth_NN the_DT suspensions_NNS were_VBD centrifuged_VBN at_IN 1,000_CD x_NN g_NN for_IN 15_CD min_NN ,_, the_DT supernatants_NNS were_VBD discarded_VBN ,_, and_CC the_DT bacteria_NNS were_VBD resuspended_VBN and_CC diluted_VBN with_IN sterile_JJ saline_NN to_TO achieve_VB a_DT concentration_NN of_IN 5_CD x_SYM 1010_CD CFU/ml_NP saline_NN ._SENT The_DT organisms_NNS were_VBD resuspended_VBN in_IN fresh_JJ MH_NP broth_NN at_IN approximately_RB 5_CD x_SYM 105_CD cells/ml_NN and_CC exposed_VBN to_TO Q-D_NP and_CC vancomycin_NP (_( one_CD and_CC four_CD times_NNS the_DT MIC_NN )_) for_IN up_IN to_TO 24_CD h_NN at_IN 37C_JJ ._SENT Throughout_IN the_DT experiments_NNS ,_, triplicate_JJ samples_NNS (_( 0.1_CD ml_NN )_) were_VBD withdrawn_VBN after_IN 0_CD ,_, 1_CD ,_, 3_CD ,_, 6_CD ,_, and_CC 24_CD h_NN of_IN incubation_NN at_IN 37C_JJ ._SENT Up_RB to_TO seven_CD 10-fold_NN dilutions_NNS were_VBD made_VBN in_IN MH_NP broth_NN from_IN each_DT sample_NN ,_, and_CC ,_, finally_RB ,_, the_DT dilutions_NNS were_VBD spread_VBN onto_IN MH_NP agar_NN plates_NNS and_CC incubated_VBN for_IN up_IN to_TO 72_CD h_NN at_IN 37C_JJ to_TO obtain_VB viable_JJ colonies_NNS ._SENT The_DT limit_NN of_IN detection_NN for_IN this_DT method_NN was_VBD approximately_RB 10_CD CFU/ml_NN ._SENT In_IN preliminary_JJ experiments_NNS ,_, antibiotic_JJ carryover_NN was_VBD ruled_VBN out_RP by_IN plating_VBG samples_NNS of_IN bacterial_JJ suspensions_NNS in_IN the_DT presence_NN or_CC absence_NN of_IN antibiotics_NNS ._SENT In_IN vivo_JJ studies_NNS ._SENT (_( i_NP )_) Rat_NP model_NN ._SENT |_SYM Adult_NP male_JJ Wistar_NP rats_NNS (_( weight_NN range_NN ,_, 250_CD to_TO 300_CD g_NN )_) were_VBD studied_VBN ._SENT The_DT study_NN included_VBD a_DT group_NN with_IN no_DT graft_NN contamination_NN and_CC no_DT local_JJ antibiotic_JJ treatment_NN (_( uncontaminated_JJ control_NN group_NN )_) ,_, one_CD contaminated_JJ group_NN that_WDT did_VBD not_RB receive_VB any_DT local_JJ antibiotic_JJ treatment_NN (_( untreated_JJ control_NN group_NN )_) ,_, two_CD contaminated_JJ groups_NNS that_WDT received_VBD grafts_NNS soaked_VBN with_IN 10_CD and_CC 100_CD mug_NN of_IN Q-D_NNS per_IN ml_NN ,_, respectively_RB ,_, and_CC two_CD contaminated_JJ groups_NNS that_WDT received_VBD grafts_NNS soaked_VBN with_IN 10_CD and_CC 100_CD mug_NN of_IN vancomycin_NP per_IN ml_NN ,_, respectively_RB ._SENT Each_DT group_NN included_VBD 20_CD animals_NNS ._SENT Rats_NNS were_VBD anesthetized_VBN with_IN ether_NN ,_, the_DT hair_NN on_IN the_DT back_NN was_VBD shaved_VBN ,_, and_CC the_DT skin_NN was_VBD cleansed_VBN with_IN 10_CD %_NN povidone-iodine_NN solution_NN ._SENT One_CD subcutaneous_JJ pocket_NN was_VBD made_VBN on_IN each_DT side_NN of_IN the_DT median_JJ line_NN through_IN a_DT 1.5-cm_NP incision_NN ._SENT Aseptically_RB ,_, 1-cm2_JJ sterile_JJ collagen-sealed_JJ Dacron_NP grafts_NNS (_( Albograft_NP ;_: Sorin_NP Biomedica_NP Cardio_NP ,_, Saluggia_NP VC_NP ,_, Italy_NP )_) were_VBD implanted_VBN into_IN the_DT pockets_NNS ._SENT Before_IN implantation_NN ,_, the_DT Dacron_NP graft_NN segments_NNS were_VBD impregnated_VBN with_IN Q-D_NP and_CC vancomycin_NP ,_, each_DT at_IN concentrations_NNS of_IN 10_CD and_CC 100_CD mug/ml_NN ._SENT Immediately_RB before_IN implantation_NN the_DT grafts_NNS were_VBD soaked_VBN for_IN 20_CD min_NN in_IN a_DT sterile_JJ solution_NN of_IN the_DT agents_NNS mentioned_VBN above_IN ._SENT The_DT pockets_NNS were_VBD closed_VBN with_IN skin_NN clips_NNS ,_, and_CC sterile_JJ saline_JJ solution_NN (_( 1_CD ml_NN )_) containing_VBG the_DT VISE_NP strain_NN at_IN a_DT concentration_NN of_IN 2_CD x_SYM 107_CD CFU/ml_NP was_VBD inoculated_VBN onto_IN the_DT graft_NN surface_NN by_IN using_VBG a_DT tuberculin_NN syringe_NN to_TO create_VB a_DT subcutaneous_JJ fluid-filled_JJ pocket_NN ._SENT The_DT animals_NNS were_VBD returned_VBN to_TO individual_JJ cages_NNS and_CC thoroughly_RB examined_VBD daily_JJ ._SENT All_DT grafts_NNS were_VBD explanted_VBN at_IN 7_CD days_NNS following_VBG implantation_NN ._SENT This_DT study_NN was_VBD approved_VBN by_IN the_DT Animal_NP Research_NP Ethics_NP Committee_NP of_IN the_DT Istituto_NP Nazionale_NP Riposo_NP e_NP Cura_NP Anziani_NP Istituto_NP di_NP Ricovero_NP e_SYM Cura_NP a_DT Carattere_NP Scientifico_NP ,_, University_NP of_IN Ancona_NP ._SENT (_( ii_NP )_) Assessment_NP of_IN infection_NN ._SENT |_SYM The_DT explanted_VBN grafts_NNS were_VBD placed_VBN in_IN sterile_JJ tubes_NNS ,_, washed_VBN in_IN sterile_JJ saline_JJ solution_NN ,_, placed_VBN in_IN tubes_NNS containing_VBG 10_CD ml_NN of_IN phosphate-buffered_JJ saline_JJ solution_NN ,_, and_CC sonicated_VBD for_IN 5_CD min_NN to_TO remove_VB the_DT adherent_JJ bacteria_NNS from_IN the_DT grafts_NNS ._SENT Quantitation_NN of_IN viable_JJ bacteria_NNS was_VBD performed_VBN by_IN culturing_VBG serial_JJ 10-fold_NN dilutions_NNS (_( 0.1_CD ml_NN )_) of_IN the_DT bacterial_JJ suspension_NN onto_IN blood_NN agar_NN plates_NNS ._SENT All_DT plates_NNS were_VBD incubated_VBN at_IN 37C_JJ for_IN 48_CD h_NN and_CC evaluated_VBN for_IN the_DT presence_NN of_IN the_DT VISE_NP strain_NN ._SENT The_DT organisms_NNS were_VBD quantitated_VBN by_IN counting_VBG the_DT number_NN of_IN CFU_NP per_IN plate_NN ._SENT The_DT limit_NN of_IN detection_NN for_IN this_DT method_NN was_VBD approximately_RB 10_CD CFU/ml_NN ._SENT Statistical_JJ analysis_NN ._SENT |_SYM MICs_NP are_VBP presented_VBN as_IN the_DT modes_NNS of_IN three_CD separate_JJ experiments_NNS ._SENT Quantitative_JJ culture_NN results_NNS regarding_VBG the_DT in_IN vivo_JJ experiments_NNS are_VBP presented_VBN as_IN the_DT means_NN +-_NN standard_JJ deviations_NNS of_IN the_DT means_NNS ._SENT The_DT results_NNS were_VBD compared_VBN by_IN analysis_NN of_IN variance_NN of_IN the_DT log-transformed_JJ data_NNS by_IN the_DT Tukey-Kramer_NP honestly_RB significant_JJ difference_NN test_NN ._SENT Significance_NN was_VBD accepted_VBN when_WRB the_DT P_NN value_NN was_VBD <=0.05_JJ ._SENT In_IN vitro_NN data_NNS ._SENT |_SYM According_VBG to_TO the_DT broth_NN microdilution_NN method_NN recommended_VBN by_IN the_DT NCCLS_NP ,_, vancomycin_NP MICs_NP were_VBD 0.25_CD and_CC 8_CD mug/ml_NN for_IN S._NP epidermidis_NNS ATCC_NP 12228_CD and_CC the_DT VISE_NP strain_NN ,_, respectively_RB ,_, while_IN Q-D_NP MICs_NP were_VBD 0.50_CD and_CC 1_CD mug/ml_NN ,_, respectively_RB ._SENT The_DT different_JJ patterns_NNS of_IN susceptibility_NN were_VBD confirmed_VBN by_IN the_DT disk_NN diffusion_NN test_NN :_: S._NP epidermidis_NNS ATCC_NP 12228_CD showed_VBD zone_NN sizes_NNS of_IN 18_CD mm_NN with_IN the_DT vancomycin_NP disc_NN ,_, while_IN the_DT intermediate_JJ resistance_NN of_IN the_DT VISE_NP strain_NN to_TO vancomycin_NP was_VBD demonstrated_VBN by_IN a_DT zone_NN size_NN of_IN 11_CD mm_NN ._SENT Q-D_NNS at_IN 2_CD mug/ml_NN (_( four_CD times_NNS the_DT MIC_NN )_) produced_VBN reductions_NNS in_IN bacterial_JJ counts_NNS of_IN 0.1_CD ,_, 0.3_CD ,_, 1.1_CD ,_, and_CC 1.8_CD log10_NN CFU/ml_NN after_IN 1_CD ,_, 3_CD ,_, 6_CD ,_, and_CC 24_CD h_NN of_IN incubation_NN ,_, respectively_RB ._SENT This_DT killing_NN was_VBD comparable_JJ to_TO that_DT obtained_VBN with_IN Q-D_NNS at_IN 0.5_CD mug/ml_NN (_( one_CD time_NN the_DT MIC_NN )_) ._SENT Vancomycin_NP at_IN 32_CD mug/ml_NN (_( four_CD times_NNS the_DT MIC_NN )_) produced_VBN reductions_NNS in_IN bacterial_JJ counts_NNS of_IN 0.2_CD ,_, 0.5_CD ,_, 1.0_CD ,_, and_CC 1.6_CD log10_NN CFU/ml_NN after_IN 1_CD ,_, 3_CD ,_, 6_CD ,_, and_CC 24_CD h_NN of_IN incubation_NN ,_, respectively_RB ,_, while_IN vancomycin_NP at_IN 8_CD mug/ml_NN (_( one_CD time_NN the_DT MIC_NN )_) exhibited_VBD a_DT low_JJ level_NN of_IN bactericidal_JJ activity_NN ,_, producing_VBG reductions_NNS in_IN bacterial_JJ counts_NNS of_IN 0.0_CD ,_, 0.1_CD ,_, 0.4_CD ,_, and_CC 0.6_CD log10_NN CFU/ml_NN ,_, respectively_RB (_( data_NNS not_RB shown_VBN )_) ._SENT In_IN vivo_JJ studies_NNS ._SENT |_SYM None_NN of_IN the_DT animals_NNS included_VBD in_IN the_DT uncontaminated_JJ control_NN group_NN had_VBD microbiological_JJ evidence_NN of_IN graft_NN infection_NN ._SENT On_IN the_DT contrary_NN ,_, all_DT 20_CD rats_NNS included_VBN in_IN the_DT untreated_JJ control_NN group_NN demonstrated_VBD evidence_NN of_IN graft_NN infection_NN ,_, with_IN quantitative_JJ culture_NN results_NNS showing_VBG 5.1_CD x_SYM 106_CD +-_NN 8.8_CD x_SYM 105_CD CFU/ml_NP ._SENT Interestingly_RB ,_, only_RB the_DT group_NN with_IN Dacron_NP grafts_NNS soaked_VBD in_IN 100_CD mug_NN of_IN Q-D_NNS per_IN ml_NN showed_VBD no_DT evidence_NN of_IN staphylococcal_JJ infection_NN (_( <10_NP CFU/ml_NP )_) ._SENT In_IN contrast_NN ,_, the_DT quantitative_JJ graft_NN cultures_NNS for_IN the_DT rats_NNS that_WDT received_VBD Dacron_NP grafts_NNS soaked_VBD in_IN 10_CD mug_NN of_IN Q-D_NNS per_IN ml_NN and_CC Dacron_NN grafts_NNS soaked_VBN in_IN vancomycin_NP demonstrated_VBD bacterial_JJ growth_NN ._SENT None_NN of_IN the_DT animals_NNS included_VBD in_IN any_DT group_NN died_VBN or_CC had_VBD clinical_JJ evidence_NN of_IN drug-related_JJ adverse_JJ effects_NNS ,_, such_JJ as_IN local_JJ signs_NNS of_IN perigraft_NN inflammation_NN ,_, anorexia_NN ,_, vomiting_NN ,_, diarrhea_NN ,_, or_CC behavioral_JJ alterations_NNS ._SENT There_EX were_VBD significant_JJ differences_NNS in_IN the_DT results_NNS of_IN the_DT quantitative_JJ bacterial_JJ graft_NN cultures_NNS when_WRB the_DT data_NNS obtained_VBN for_IN the_DT antibiotic-treated_JJ groups_NNS were_VBD compared_VBN with_IN those_DT obtained_VBN for_IN the_DT contaminated_JJ control_NN group_NN (_( P_NN <_SYM 0.05_CD )_) ,_, with_IN the_DT exception_NN of_IN the_DT group_NN treated_VBN with_IN grafts_NNS soaked_VBN in_IN 10_CD mug_NN of_IN vancomycin_NP per_IN ml_NN ._SENT When_WRB data_NNS obtained_VBD for_IN each_DT group_NN with_IN grafts_NNS soaked_VBN in_IN an_DT antibiotic_NN were_VBD compared_VBN with_IN those_DT obtained_VBN for_IN any_DT other_JJ group_NN with_IN a_DT graft_NN soaked_VBN in_IN an_DT antibiotic_NN ,_, the_DT differences_NNS were_VBD always_RB statistically_RB significant_JJ for_IN grafts_NNS soaked_VBN in_IN 100_CD mug_NN of_IN Q-D_NNS per_IN ml_NN (_( P_NN <_SYM 0.05_CD )_) ._SENT Finally_RB ,_, no_DT statistically_RB significant_JJ differences_NNS were_VBD observed_VBN between_IN the_DT group_NN with_IN grafts_NNS soaked_VBN in_IN 10_CD mug_NN of_IN Q-D_NNS per_IN ml_NN and_CC the_DT group_NN with_IN grafts_NNS soaked_VBN in_IN 100_CD mug_NN of_IN vancomycin_NP per_IN ml_NN ._SENT TABLE_NN 1_CD |_SYM Efficacies_NN of_IN Q-D_NP and_CC vancomycin_NP against_IN a_DT glycopeptide-intermediate_JJ S._NP epidermidis_NNS strain_VBP causing_VBG graft_NN infection_NN in_IN a_DT rat_NN model_NN Debate_NN continues_VBZ over_IN the_DT best_JJS treatment_NN for_IN prosthetic_JJ vascular_JJ graft_NN infections_NNS ._SENT S._NP epidermidis_NP is_VBZ the_DT most_RBS important_JJ pathogen_NN causing_VBG infections_NNS related_VBN to_TO implanted_VBN foreign_JJ bodies_NNS ._SENT It_PP has_VBZ been_VBN recovered_VBN from_IN the_DT skin_NN ,_, subcutaneous_JJ fat_NN ,_, lymph_NN nodes_NNS ,_, and_CC arterial_JJ walls_NNS of_IN more_JJR than_IN one-third_NN of_IN individuals_NNS undergoing_VBG vascular_JJ reconstruction_NN ,_, despite_IN the_DT use_NN of_IN aseptic_JJ vascular_JJ surgical_JJ technique_NN and_CC prophylactic_JJ antibiotics_NNS ._SENT Most_RBS important_JJ in_IN the_DT pathogenesis_NN of_IN foreign_JJ body-associated_JJ infection_NN due_JJ to_TO this_DT organism_NN is_VBZ the_DT colonization_NN of_IN the_DT polymer_NN surface_NN by_IN formation_NN of_IN a_DT biofilm_NN ._SENT For_IN this_DT reason_NN ,_, prevention_NN through_IN effective_JJ antibiotic_JJ prophylaxis_NN plays_VBZ a_DT pivotal_JJ role_NN in_IN the_DT control_NN of_IN these_DT infections_NNS and_CC has_VBZ an_DT important_JJ impact_NN on_IN patient_JJ mortality_NN and_CC the_DT cost-effectiveness_NN of_IN hospital_NN care_NN ._SENT The_DT success_NN of_IN prophylactic_JJ antibiotics_NNS during_IN surgery_NN is_VBZ dependent_JJ on_IN the_DT pharmacokinetics_NN of_IN the_DT antibiotic_NN in_IN tissue_NN and_CC the_DT maintenance_NN of_IN adequate_JJ levels_NNS of_IN the_DT antibiotic_NN in_IN tissue_NN for_IN the_DT duration_NN of_IN the_DT vascular_JJ surgical_JJ procedure_NN ._SENT Nevertheless_RB ,_, errors_NNS in_IN the_DT sterilization_NN procedures_NNS and_CC the_DT increases_NNS in_IN the_DT incidence_NN and_CC the_DT levels_NNS of_IN resistance_NN of_IN S._NP epidermidis_NNS can_MD predispose_VB individuals_NNS to_TO prosthesis_NN infections_NNS ._SENT Glycopeptides_NNS such_JJ as_IN vancomycin_NP are_VBP used_VBN parenterally_RB to_TO treat_VB infections_NNS caused_VBN by_IN gram-positive_JJ bacteria_NNS ,_, especially_RB staphylococcal_JJ infections_NNS after_IN the_DT emergence_NN of_IN methicillin-resistant_JJ staphylococci_NNS ._SENT Recently_RB ,_, they_PP have_VBP been_VBN administered_VBN as_IN perioperative_JJ antibiotic_JJ prophylaxis_NN ._SENT Nevertheless_RB ,_, the_DT recent_JJ emergence_NN of_IN glycopeptide_NNS resistance_NN in_IN coagulase-negative_JJ staphylococci_NNS heightens_VBZ concern_NN about_IN the_DT need_NN for_IN other_JJ antistaphylococcal_JJ agents_NNS ._SENT Analysis_NN of_IN the_DT data_NNS from_IN in_IN vitro_NN studies_NNS shows_VBZ that_IN Q-D_NP and_CC vancomycin_NP had_VBD similar_JJ activities_NNS against_IN the_DT control_NN strain_NN ,_, S._NP epidermidis_NNS ATCC_NP 12228_CD ,_, while_IN Q-D_NP exhibited_VBD a_DT higher_JJR level_NN of_IN activity_NN than_IN vancomycin_NP against_IN the_DT VISE_NP clinical_JJ strain_NN ._SENT In_IN fact_NN ,_, the_DT broth_NN microdilution_NN method_NN and_CC the_DT disk_NN diffusion_NN method_NN recommended_VBN by_IN the_DT NCCLS_NP showed_VBD that_IN vancomycin_NP exerted_VBD intermediate_JJ activity_NN against_IN the_DT VISE_NP strain_NN ,_, although_IN there_EX are_VBP still_RB differences_NNS between_IN the_DT current_JJ NCCLS_NP interpretive_JJ standards_NNS and_CC the_DT recommendations_NNS made_VBD to_TO define_VB categories_NNS of_IN susceptibility_NN to_TO glycopeptides_NNS in_IN some_DT other_JJ countries_NNS ._SENT The_DT in_IN vivo_JJ results_NNS were_VBD similar_JJ to_TO those_DT reported_VBN by_IN other_JJ investigators_NNS ,_, who_WP found_VBD that_IN the_DT use_NN of_IN Dacron_NP grafts_NNS soaked_VBN in_IN an_DT antibiotic_NN can_MD result_VB in_IN significant_JJ bacterial_JJ growth_NN inhibition_NN ,_, even_RB though_IN high_JJ concentrations_NNS of_IN organisms_NNS were_VBD topically_RB inoculated_VBN on_IN the_DT Dacron_NP prostheses_NNS ._SENT Actually_RB ,_, statistical_JJ analysis_NN demonstrated_VBD that_IN any_DT prophylactic_JJ antibiotic_JJ treatment_NN except_IN vancomycin_NP at_IN 10_CD mug/ml_NN was_VBD useful_JJ ._SENT Nevertheless_RB only_RB Q-D_JJ at_IN the_DT highest_JJS concentration_NN tested_VBD inhibited_VBN bacterial_JJ growth_NN within_IN the_DT limits_NNS of_IN detection_NN ._SENT Finally_RB ,_, no_DT statistically_RB significant_JJ differences_NNS were_VBD observed_VBN between_IN the_DT groups_NNS that_WDT received_VBD grafts_NNS soaked_VBN with_IN 10_CD mug_NN of_IN Q-D_NNS per_IN ml_NN and_CC those_DT that_WDT received_VBD grafts_NNS soaked_VBN with_IN 100_CD mug_NN of_IN vancomycin_NP per_IN ml_NN ._SENT However_RB ,_, it_PP is_VBZ noteworthy_JJ that_IN Q-D_NP and_CC vancomycin_NP are_VBP physically_RB different_JJ compounds_NNS and_CC the_DT quantitative_JJ results_NNS could_MD be_VB affected_VBN by_IN the_DT lack_NN of_IN equivalent_JJ abilities_NNS of_IN the_DT two_CD antibiotics_NNS to_TO coat_VB the_DT artificial_JJ materials_NNS ._SENT It_PP has_VBZ long_RB been_VBN recognized_VBN that_IN the_DT treatment_NN of_IN serious_JJ bacteremia_NN caused_VBN by_IN staphylococci_NNS ,_, such_JJ as_IN vascular_JJ graft_NN infection_NN ,_, typically_RB requires_VBZ the_DT use_NN of_IN agents_NNS with_IN bactericidal_JJ activities_NNS against_IN the_DT organism_NN ._SENT This_DT fact_NN is_VBZ likely_RB emphasized_VBN by_IN the_DT recent_JJ emergence_NN in_IN clinical_JJ settings_NNS of_IN multidrug-resistant_JJ bacteria_NNS that_WDT belong_VBP ,_, for_IN the_DT most_JJS part_NN ,_, to_TO the_DT staphylococcal_JJ species_NN ._SENT New_JJ therapeutic_JJ options_NNS are_VBP needed_VBN ,_, although_IN experience_NN demonstrates_VBZ that_IN every_DT new_JJ antimicrobial_JJ agent_NN introduced_VBN into_IN clinical_JJ practice_NN can_MD be_VB plagued_VBN by_IN the_DT emergence_NN of_IN organisms_NNS resistant_JJ to_TO its_PP$ effect_NN ._SENT The_DT strong_JJ in_IN vitro_NN activity_NN and_CC the_DT prophylactic_NN in_IN vivo_JJ efficacy_NN demonstrated_VBN by_IN Q-D_NNS against_IN a_DT staphylococcal_JJ strain_NN with_IN decreased_VBN susceptibility_NN to_TO the_DT glycopeptides_NNS used_VBN in_IN the_DT present_JJ study_NN make_VB Q-D_NNS potentially_RB useful_JJ for_IN future_JJ topical_JJ antimicrobial_JJ treatments_NNS ,_, such_JJ as_IN perioperative_JJ chemoprophylaxis_NN in_IN prosthetic_JJ surgery_NN ._SENT 